Scilex Holding Company
SCLX Healthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024. In the quarter to June 2026, revenue fell 22.8%, EPS fell 124.4%, free cash flow fell 203.8% and total debt rose 102.7%, each against the same quarter a year earlier.
Follow SCLX
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
0.88 | 10.98 | 3.36 | 0.58 |
Receivables |
11.94 | 15.24 | 10.65 | 6.44 | |
Inventory |
1.08 | 4.79 | 4.53 | 4.17 | |
Total current assets |
16.49 | 38.36 | 41.97 | 36.24 | |
Property, Plant, Equpment (Net) |
0.70 | 13.60 | 13.38 | 12.77 | |
Long-Term Investments |
16.35 | 160.40 | 83.93 | 61.74 | |
Goodwill and Intangible Assets (Total) |
240.54 | 137.28 | 138.63 | 127.23 | |
Long-term assets (Other) |
0.12 | 0.52 | 1.55 | 1.55 | |
Total non-current assets |
259.39 | 326.62 | 251.67 | 217.33 | |
Total Assets |
275.88 | 364.98 | 293.64 | 253.56 | |
Notes Payable |
4.48 | 3.52 | 2.77 | 2.23 | |
Accounts Payable |
67.36 | 86.27 | 101.58 | 121.05 | |
Accrued Expenses |
235.86 | 301.44 | 311.45 | 299.15 | |
Current Part of Debt |
45.67 | 83.26 | 80.78 | 80.81 | |
Current Revenue (Deferred) |
0.42 | 0.41 | 0.40 | 0.39 | |
Other current liabilities |
4.36 | 7.03 | 3.05 | 6.37 | |
Total current liabilities |
358.95 | 483.65 | 501.75 | 512.24 | |
Non-current Revenue (Deferred) |
2.14 | 2.04 | 1.95 | 1.85 | |
Non-current Liabilities (Other) |
93.59 | 77.89 | 31.32 | 37.45 | |
Total non-current liabilities |
96.65 | 93.08 | 45.95 | 51.81 | |
Total liabilities |
455.60 | 576.73 | 547.71 | 564.05 | |
Additional Paid In Capital |
785.30 | 796.72 | 799.30 | 854.13 | |
Preferred Stock (Total) |
0.00 | 0.00 | — | — | |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | |
Retained Earnings |
(888.67) | (921.79) | (965.06) | (1,078.56) | |
Treasury Stock |
76.92 | 76.92 | 76.92 | 76.92 | |
Common Equity (Total) |
(179.72) | (211.75) | (254.07) | (310.49) | |
Shareholders Equity (Total) |
(179.72) | (211.75) | (254.07) | (310.49) | |
Shareholders Equity and Liabilities (Total) |
275.88 | 364.98 | 293.64 | 253.56 | |
Shares (Common) |
5.95 | 7.03 | 7.03 | 7.04 | |
Shares (Preferred) |
29.06 | 29.06 | 29.06 | 29.06 | |
Shareholders Equity (Tangible) |
(420.25) | (349.03) | (392.70) | (437.72) | |
Net Debt |
44.80 | 72.28 | 77.42 | 80.23 | |
Total Debt |
45.67 | 83.26 | 80.78 | 80.81 |